SpringWorks Therapeutics has received US approval for its second commercial product just a day after Merck KGaA confirmed rumors that it was in advanced negotiations to acquire the US biotech.
SpringWorks Gains New Approval Amid Merck KGaA Buyout Talks
After coming up blank with its in-house oncology efforts, the German conglomerate is mulling a deal to acquire the US specialist company which has just managed a new drug approval for mirdametinib.
More from Deals
More from Therapy Areas
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.